Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
58 hedge funds and large institutions have $270M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$85.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$33.5M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$23.6M |
| 4 |
PI
Pharmstandard International
Luxembourg
|
+$14M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$12.3M |
Top Sellers
JNCE Hedge Fund Activity: Q1 2017 in Review
58 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2017, worth a combined $270M.
Buyers outnumbered sellers: 58 funds opened new JNCE positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $85.7M.
- 58 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2017, up from 0 in Q4 2016.
- Funds reported $270M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2017.
- 58 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2017 and 0 closed out, a net change of +58 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2017 was Fidelity Investments, an estimated $85.7M added.
Based on aggregated 13F filings for Q1 2017.